Investment Analysts’ Weekly Ratings Changes for uniQure (QURE)

A number of research firms have changed their ratings and price targets for uniQure (NASDAQ: QURE):

• 11/6/2024 – uniQure had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $28.00 price target on the stock.
• 11/6/2024 – uniQure had its price target lowered by analysts at Royal Bank of Canada from $16.00 to $14.00. They now have an “outperform” rating on the stock.
• 11/6/2024 – uniQure had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $10.00 to $9.00. They now have a “neutral” rating on the stock.
• 11/6/2024 – uniQure had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
• 10/17/2024 – uniQure was upgraded by analysts at StockNews.com to a “sell” rating.
• 10/10/2024 – uniQure had its “outperform” rating reaffirmed by analysts at Raymond James. They now have a $20.00 price target on the stock.

uniQure Trading Up 1.0 %

QURE opened at $6.05 on Wednesday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The stock has a market capitalization of $294.88 million, a PE ratio of -1.22 and a beta of 0.90. uniQure has a 12-month low of $3.73 and a 12-month high of $11.35. The firm’s fifty day moving average price is $5.95 and its 200 day moving average price is $5.98.

uniQure (NASDAQ:QURE) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.12) by $0.21. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%. As a group, research analysts expect that uniQure will post -3.81 EPS for the current fiscal year.

Institutional Investors Weigh In On uniQure

Hedge funds and other institutional investors have recently modified their holdings of the stock. abrdn plc lifted its holdings in shares of uniQure by 381.7% in the third quarter. abrdn plc now owns 1,929,061 shares of the biotechnology company’s stock valued at $9,510,000 after buying an additional 1,528,581 shares during the period. Vanguard Group Inc. raised its holdings in shares of uniQure by 11.4% in the 1st quarter. Vanguard Group Inc. now owns 1,072,536 shares of the biotechnology company’s stock worth $5,577,000 after purchasing an additional 109,740 shares in the last quarter. Point72 Asset Management L.P. lifted its stake in uniQure by 336.1% during the third quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company’s stock valued at $4,816,000 after purchasing an additional 752,889 shares during the last quarter. Privium Fund Management B.V. grew its position in uniQure by 16.3% in the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after buying an additional 104,500 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of uniQure by 1.3% in the third quarter. Geode Capital Management LLC now owns 508,602 shares of the biotechnology company’s stock valued at $2,509,000 after buying an additional 6,362 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.